A retrospective cohort study of the effectiveness and safety of dabigatran versus rivaroxaban in overweight patients with nonvalvular atrial fibrillation View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-07-17

AUTHORS

Meixiang Yu, Zi Wang, Liuliu Zong, Qing Xu, Xiaoye Li, Qianzhou Lv

ABSTRACT

BackgroundGuidance for dabigatran and rivaroxaban in overweight patients diagnosed with non-valvular atrial fibrillation (NVAF) is still lacking.AimCompare the effectiveness and safety of dabigatran and rivaroxaban for the treatment of NVAF in the overweight population.MethodA total of 396 out of 1029 overweight patients with NVAF at Zhongshan Hospital, Fudan University, from January 2017 and December 2018 were retrospectively enrolled using propensity score matching analysis. The clinical outcomes were analyzed by chi-square test and Kaplan–Meier analyses. The risk of bleeding and thrombosis was assessed using a Cox regression analysis and validated using a nomogram model.ResultsIn terms of effectiveness, the incidence of thrombosis events and the time to thrombosis were similar in the dabigatran and rivaroxaban groups (P > 0.05). Regarding safety, compared to dabigatran, the rivaroxaban group had a higher incidence of bleeding events (8.6% vs. 3.5%, χ2 = 4.435, P = 0.035), a shorter time to bleeding (11.3 ± 0.18 months vs. 11.6 ± 0.14 months, P = 0.038) and an increased risk of bleeding (hazard ratio HR = 2.452, 95% confidence interval CI 1.017–5.913, P = 0.046), especially in those patients with heart failure (HR = 3.207, 95% CI 1.183–8.694, P = 0.022).ConclusionDabigatran therapy was shown to be equally effective. It may be superior in reducing bleeding risk in an overweight population with NVAF than rivaroxaban. Further prospective studies are encouraged for analysis. More... »

PAGES

1149-1157

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11096-022-01443-2

DOI

http://dx.doi.org/10.1007/s11096-022-01443-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1149535176

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35842869


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dabigatran", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rivaroxaban", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atrial Fibrillation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Warfarin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Overweight", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticoagulants", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemorrhage", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stroke", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/grid.413087.9", 
          "name": [
            "Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yu", 
        "givenName": "Meixiang", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/grid.413087.9", 
          "name": [
            "Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Zi", 
        "id": "sg:person.014234544715.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014234544715.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/grid.413087.9", 
          "name": [
            "Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zong", 
        "givenName": "Liuliu", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/grid.413087.9", 
          "name": [
            "Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xu", 
        "givenName": "Qing", 
        "id": "sg:person.07412333113.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07412333113.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/grid.413087.9", 
          "name": [
            "Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Xiaoye", 
        "id": "sg:person.015261673174.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015261673174.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/grid.413087.9", 
          "name": [
            "Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lv", 
        "givenName": "Qianzhou", 
        "id": "sg:person.0600517053.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600517053.59"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10654-017-0232-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083805791", 
          "https://doi.org/10.1007/s10654-017-0232-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11239-015-1310-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008818758", 
          "https://doi.org/10.1007/s11239-015-1310-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40256-019-00362-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1119797323", 
          "https://doi.org/10.1007/s40256-019-00362-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11096-021-01309-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1140006846", 
          "https://doi.org/10.1007/s11096-021-01309-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11318100-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040691762", 
          "https://doi.org/10.2165/11318100-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11096-019-00830-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1113639936", 
          "https://doi.org/10.1007/s11096-019-00830-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-07-17", 
    "datePublishedReg": "2022-07-17", 
    "description": "BackgroundGuidance for dabigatran and rivaroxaban in overweight patients diagnosed with non-valvular atrial fibrillation (NVAF) is still lacking.AimCompare the effectiveness and safety of dabigatran and rivaroxaban for the treatment of NVAF in the overweight population.MethodA total of 396 out of 1029 overweight patients with NVAF at Zhongshan Hospital, Fudan University, from January 2017 and December 2018 were retrospectively enrolled using propensity score matching analysis. The clinical outcomes were analyzed by chi-square test and Kaplan\u2013Meier analyses. The risk of bleeding and thrombosis was assessed using a Cox regression analysis and validated using a nomogram model.ResultsIn terms of effectiveness, the incidence of thrombosis events and the time to thrombosis were similar in the dabigatran and rivaroxaban groups (P\u2009>\u20090.05). Regarding safety, compared to dabigatran, the rivaroxaban group had a higher incidence of bleeding events (8.6% vs. 3.5%, \u03c72\u2009=\u20094.435, P\u2009=\u20090.035), a shorter time to bleeding (11.3\u2009\u00b1\u20090.18\u00a0months vs. 11.6\u2009\u00b1\u20090.14\u00a0months, P\u2009=\u20090.038) and an increased risk of bleeding (hazard ratio HR\u2009=\u20092.452, 95% confidence interval CI 1.017\u20135.913, P\u2009=\u20090.046), especially in those patients with heart failure (HR\u2009=\u20093.207, 95% CI 1.183\u20138.694, P\u2009=\u20090.022).ConclusionDabigatran therapy was shown to be equally effective. It may be superior in reducing bleeding risk in an overweight population with NVAF than rivaroxaban. Further prospective studies are encouraged for analysis.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11096-022-01443-2", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1044817", 
        "issn": [
          "2210-7703", 
          "2210-7711"
        ], 
        "name": "International Journal of Clinical Pharmacy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "keywords": [
      "non-valvular atrial fibrillation", 
      "safety of dabigatran", 
      "overweight patients", 
      "rivaroxaban group", 
      "atrial fibrillation", 
      "overweight population", 
      "treatment of NVAF", 
      "retrospective cohort study", 
      "nonvalvular atrial fibrillation", 
      "risk of bleeding", 
      "Kaplan-Meier analysis", 
      "Cox regression analysis", 
      "Further prospective studies", 
      "chi-square test", 
      "cohort study", 
      "thrombosis events", 
      "heart failure", 
      "Zhongshan Hospital", 
      "clinical outcomes", 
      "nomogram model", 
      "prospective study", 
      "dabigatran", 
      "high incidence", 
      "rivaroxaban", 
      "MethodA total", 
      "patients", 
      "Fudan University", 
      "propensity score", 
      "ResultsIn terms", 
      "thrombosis", 
      "regression analysis", 
      "fibrillation", 
      "incidence", 
      "risk", 
      "safety", 
      "bleeding", 
      "group", 
      "hospital", 
      "therapy", 
      "population", 
      "outcomes", 
      "treatment", 
      "total", 
      "scores", 
      "study", 
      "events", 
      "failure", 
      "effectiveness", 
      "short time", 
      "analysis", 
      "time", 
      "test", 
      "University", 
      "model", 
      "terms"
    ], 
    "name": "A retrospective cohort study of the effectiveness and safety of dabigatran versus rivaroxaban in overweight patients with nonvalvular atrial fibrillation", 
    "pagination": "1149-1157", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1149535176"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11096-022-01443-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35842869"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11096-022-01443-2", 
      "https://app.dimensions.ai/details/publication/pub.1149535176"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:09", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_932.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11096-022-01443-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11096-022-01443-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11096-022-01443-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11096-022-01443-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11096-022-01443-2'


 

This table displays all metadata directly associated to this object as RDF triples.

221 TRIPLES      21 PREDICATES      98 URIs      84 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11096-022-01443-2 schema:about N07e77036c72a41d2968d182544c6e4b6
2 N08abf70444b94f4f95a77d9566e047c0
3 N123a198a4e4c4320b9a0fbca487d3726
4 N2ace46f7409b439fb9d1214fac93884f
5 N2ea0f5a0fd4643e9b07428281ebf0e3b
6 N3066af943bcb45a48fe5c2ed06782286
7 N3352659dc9e04c6087a3a219e46fa73c
8 N36d2b137af11411b92a3e872262fefaf
9 N51615dc60dcf40b7ade265bdfd7e1303
10 N7c3274312f7749bb985ac15bde0290e7
11 N8e3126340eb64652a0418f98fbe03cbb
12 N985c1ff09d2d4a83ade6d4185629d786
13 anzsrc-for:11
14 anzsrc-for:1102
15 schema:author N72b909f30526496d9e968ea4c84b97fc
16 schema:citation sg:pub.10.1007/s10654-017-0232-4
17 sg:pub.10.1007/s11096-019-00830-6
18 sg:pub.10.1007/s11096-021-01309-z
19 sg:pub.10.1007/s11239-015-1310-7
20 sg:pub.10.1007/s40256-019-00362-4
21 sg:pub.10.2165/11318100-000000000-00000
22 schema:datePublished 2022-07-17
23 schema:datePublishedReg 2022-07-17
24 schema:description BackgroundGuidance for dabigatran and rivaroxaban in overweight patients diagnosed with non-valvular atrial fibrillation (NVAF) is still lacking.AimCompare the effectiveness and safety of dabigatran and rivaroxaban for the treatment of NVAF in the overweight population.MethodA total of 396 out of 1029 overweight patients with NVAF at Zhongshan Hospital, Fudan University, from January 2017 and December 2018 were retrospectively enrolled using propensity score matching analysis. The clinical outcomes were analyzed by chi-square test and Kaplan–Meier analyses. The risk of bleeding and thrombosis was assessed using a Cox regression analysis and validated using a nomogram model.ResultsIn terms of effectiveness, the incidence of thrombosis events and the time to thrombosis were similar in the dabigatran and rivaroxaban groups (P > 0.05). Regarding safety, compared to dabigatran, the rivaroxaban group had a higher incidence of bleeding events (8.6% vs. 3.5%, χ2 = 4.435, P = 0.035), a shorter time to bleeding (11.3 ± 0.18 months vs. 11.6 ± 0.14 months, P = 0.038) and an increased risk of bleeding (hazard ratio HR = 2.452, 95% confidence interval CI 1.017–5.913, P = 0.046), especially in those patients with heart failure (HR = 3.207, 95% CI 1.183–8.694, P = 0.022).ConclusionDabigatran therapy was shown to be equally effective. It may be superior in reducing bleeding risk in an overweight population with NVAF than rivaroxaban. Further prospective studies are encouraged for analysis.
25 schema:genre article
26 schema:isAccessibleForFree false
27 schema:isPartOf Naf11f2ed0d304eac8b1061e80b110c98
28 Nfa78bc9d2b1a4588894a4bdba45f7f08
29 sg:journal.1044817
30 schema:keywords Cox regression analysis
31 Fudan University
32 Further prospective studies
33 Kaplan-Meier analysis
34 MethodA total
35 ResultsIn terms
36 University
37 Zhongshan Hospital
38 analysis
39 atrial fibrillation
40 bleeding
41 chi-square test
42 clinical outcomes
43 cohort study
44 dabigatran
45 effectiveness
46 events
47 failure
48 fibrillation
49 group
50 heart failure
51 high incidence
52 hospital
53 incidence
54 model
55 nomogram model
56 non-valvular atrial fibrillation
57 nonvalvular atrial fibrillation
58 outcomes
59 overweight patients
60 overweight population
61 patients
62 population
63 propensity score
64 prospective study
65 regression analysis
66 retrospective cohort study
67 risk
68 risk of bleeding
69 rivaroxaban
70 rivaroxaban group
71 safety
72 safety of dabigatran
73 scores
74 short time
75 study
76 terms
77 test
78 therapy
79 thrombosis
80 thrombosis events
81 time
82 total
83 treatment
84 treatment of NVAF
85 schema:name A retrospective cohort study of the effectiveness and safety of dabigatran versus rivaroxaban in overweight patients with nonvalvular atrial fibrillation
86 schema:pagination 1149-1157
87 schema:productId N09c0fd9670ad416bbc414d5c62ff2bb5
88 Na3dba89b35e64d3d929a61551281411c
89 Nfac51caf6baf447d897aa22c5a21d66d
90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1149535176
91 https://doi.org/10.1007/s11096-022-01443-2
92 schema:sdDatePublished 2022-11-24T21:09
93 schema:sdLicense https://scigraph.springernature.com/explorer/license/
94 schema:sdPublisher N3002a651044747c58b817ad39cfe4f59
95 schema:url https://doi.org/10.1007/s11096-022-01443-2
96 sgo:license sg:explorer/license/
97 sgo:sdDataset articles
98 rdf:type schema:ScholarlyArticle
99 N07e77036c72a41d2968d182544c6e4b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Humans
101 rdf:type schema:DefinedTerm
102 N08abf70444b94f4f95a77d9566e047c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Stroke
104 rdf:type schema:DefinedTerm
105 N09c0fd9670ad416bbc414d5c62ff2bb5 schema:name dimensions_id
106 schema:value pub.1149535176
107 rdf:type schema:PropertyValue
108 N0d16b16a658c4979a916929b6fe4f4ef schema:affiliation grid-institutes:grid.413087.9
109 schema:familyName Yu
110 schema:givenName Meixiang
111 rdf:type schema:Person
112 N123a198a4e4c4320b9a0fbca487d3726 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Overweight
114 rdf:type schema:DefinedTerm
115 N2ace46f7409b439fb9d1214fac93884f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Atrial Fibrillation
117 rdf:type schema:DefinedTerm
118 N2ea0f5a0fd4643e9b07428281ebf0e3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Administration, Oral
120 rdf:type schema:DefinedTerm
121 N3002a651044747c58b817ad39cfe4f59 schema:name Springer Nature - SN SciGraph project
122 rdf:type schema:Organization
123 N3066af943bcb45a48fe5c2ed06782286 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Dabigatran
125 rdf:type schema:DefinedTerm
126 N3352659dc9e04c6087a3a219e46fa73c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Hemorrhage
128 rdf:type schema:DefinedTerm
129 N36d2b137af11411b92a3e872262fefaf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Warfarin
131 rdf:type schema:DefinedTerm
132 N51615dc60dcf40b7ade265bdfd7e1303 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Retrospective Studies
134 rdf:type schema:DefinedTerm
135 N66093f14d63b46aba9e8febc2abfa240 rdf:first Nbf6882002eb54da69c293672b4d8cd6f
136 rdf:rest N95ccf4023ec24301abc52e8943fc065e
137 N72b909f30526496d9e968ea4c84b97fc rdf:first N0d16b16a658c4979a916929b6fe4f4ef
138 rdf:rest Nd4bae823d8744cb6947865034c46eb05
139 N7c3274312f7749bb985ac15bde0290e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Prospective Studies
141 rdf:type schema:DefinedTerm
142 N8e3126340eb64652a0418f98fbe03cbb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Anticoagulants
144 rdf:type schema:DefinedTerm
145 N94b5170fffdc42f0a749a52ad96c3c3d rdf:first sg:person.0600517053.59
146 rdf:rest rdf:nil
147 N95ccf4023ec24301abc52e8943fc065e rdf:first sg:person.07412333113.29
148 rdf:rest Nf8ecffbd95624f09a996f532b18bf911
149 N985c1ff09d2d4a83ade6d4185629d786 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Rivaroxaban
151 rdf:type schema:DefinedTerm
152 Na3dba89b35e64d3d929a61551281411c schema:name doi
153 schema:value 10.1007/s11096-022-01443-2
154 rdf:type schema:PropertyValue
155 Naf11f2ed0d304eac8b1061e80b110c98 schema:volumeNumber 44
156 rdf:type schema:PublicationVolume
157 Nbf6882002eb54da69c293672b4d8cd6f schema:affiliation grid-institutes:grid.413087.9
158 schema:familyName Zong
159 schema:givenName Liuliu
160 rdf:type schema:Person
161 Nd4bae823d8744cb6947865034c46eb05 rdf:first sg:person.014234544715.32
162 rdf:rest N66093f14d63b46aba9e8febc2abfa240
163 Nf8ecffbd95624f09a996f532b18bf911 rdf:first sg:person.015261673174.04
164 rdf:rest N94b5170fffdc42f0a749a52ad96c3c3d
165 Nfa78bc9d2b1a4588894a4bdba45f7f08 schema:issueNumber 5
166 rdf:type schema:PublicationIssue
167 Nfac51caf6baf447d897aa22c5a21d66d schema:name pubmed_id
168 schema:value 35842869
169 rdf:type schema:PropertyValue
170 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
171 schema:name Medical and Health Sciences
172 rdf:type schema:DefinedTerm
173 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
174 schema:name Cardiorespiratory Medicine and Haematology
175 rdf:type schema:DefinedTerm
176 sg:journal.1044817 schema:issn 2210-7703
177 2210-7711
178 schema:name International Journal of Clinical Pharmacy
179 schema:publisher Springer Nature
180 rdf:type schema:Periodical
181 sg:person.014234544715.32 schema:affiliation grid-institutes:grid.413087.9
182 schema:familyName Wang
183 schema:givenName Zi
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014234544715.32
185 rdf:type schema:Person
186 sg:person.015261673174.04 schema:affiliation grid-institutes:grid.413087.9
187 schema:familyName Li
188 schema:givenName Xiaoye
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015261673174.04
190 rdf:type schema:Person
191 sg:person.0600517053.59 schema:affiliation grid-institutes:grid.413087.9
192 schema:familyName Lv
193 schema:givenName Qianzhou
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600517053.59
195 rdf:type schema:Person
196 sg:person.07412333113.29 schema:affiliation grid-institutes:grid.413087.9
197 schema:familyName Xu
198 schema:givenName Qing
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07412333113.29
200 rdf:type schema:Person
201 sg:pub.10.1007/s10654-017-0232-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083805791
202 https://doi.org/10.1007/s10654-017-0232-4
203 rdf:type schema:CreativeWork
204 sg:pub.10.1007/s11096-019-00830-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113639936
205 https://doi.org/10.1007/s11096-019-00830-6
206 rdf:type schema:CreativeWork
207 sg:pub.10.1007/s11096-021-01309-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1140006846
208 https://doi.org/10.1007/s11096-021-01309-z
209 rdf:type schema:CreativeWork
210 sg:pub.10.1007/s11239-015-1310-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008818758
211 https://doi.org/10.1007/s11239-015-1310-7
212 rdf:type schema:CreativeWork
213 sg:pub.10.1007/s40256-019-00362-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1119797323
214 https://doi.org/10.1007/s40256-019-00362-4
215 rdf:type schema:CreativeWork
216 sg:pub.10.2165/11318100-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040691762
217 https://doi.org/10.2165/11318100-000000000-00000
218 rdf:type schema:CreativeWork
219 grid-institutes:grid.413087.9 schema:alternateName Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China
220 schema:name Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China
221 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...